Biosimilar insulin as an alternative for the original products

Łącka-Gaździk, Beata; Śnit, Mirosław; Grzeszczak, W

doi:10.5603/dk.2016.0021

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the face of growing financial limitations and the expiration of patents protecting biologics, biosimilars are a group of products with a great future [26]. The loss of patent protection for many biologics could lead to the introduction of many biosimilars in the coming years [18].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences

Barszczewska

Piechota

2021

IJERPH

View full text Add to dashboard Cite

Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimilars of a specific original drug reduces the price of the selected API. The study focuses on drug prices varying with the successive arrival of new biosimilars. Three drugs that have at least three reimbursed biosimilars on the market were selected, two from the same therapeutic group (adalimumab and infliximab) and one (trastuzumab) representing another class of drugs. The following data were analyzed: price variation after the introduction of the first, second, and third biosimilar, and the average price reduction for all three biosimilars. Additionally, a literature review was conducted. The reimbursement of each new biosimilar is beneficial since it is associated with a price reduction in percentage terms. However, the first biosimilar brought about the greatest savings due to the higher initial prices of the original drugs and to Polish reimbursement rules. This article is helpful for when taking healthcare decisions regarding the pricing of and reimbursement for new biosimilars.

show abstract

Section: Discussionmentioning

confidence: 99%